Floatz logo

ANTI-HER2 ANTIBODY-DRUG CONJUGATE A166

HER2-positive Breast Cancer

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.antibody_drug_conjugatePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
65/ 100

Competitive context

187 Active assets in the HER2-positive Breast Cancer cohort.

Asset / SponsorPhaseRating
Vinorelbine
Jazz Pharmaceuticals
Phase 3BBB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
SWOG Cancer Research Network
Phase 4BB
Epirubicin
Shanghai JMT-Bio Inc.
Phase 3BB
TRASTUZUMAB
SWOG Cancer Research Network
Phase 4BB
Ribociclib
Danish Breast Cancer Cooperative Group
Phase 3BB

View all 50 →

Same molecule, other indications

ANTI-HER2 ANTIBODY-DRUG CONJUGATE A166 is also rated in:

breast cancerDormant
B
Indicative ·
56 / 100
View asset →
HER2 Gene MutationDormant
CCC
Indicative ·
52 / 100
View asset →
tumor of salivary glandDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →